New drug cocktail targets Hard-to-Treat myeloma

NCT ID NCT03031730

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called KRT-232 combined with three standard myeloma drugs (carfilzomib, lenalidomide, and dexamethasone) in 35 patients whose multiple myeloma had returned or stopped responding to treatment. The main goals were to check safety and find the best dose. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KRT-232 (MDM2 inhibitor) combined with carfilzomib, lenalidomide, and dexamethasone
What this could lead to: If it works, this could point toward a new treatment option for multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong: This is a very early phase 1 trial focused on safety and dosing, so it may not show strong anti-cancer effects. The study was terminated early, limiting the data available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMACYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasmacytoma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMACYTOMA RECURRENT MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229, United States
University of Texas at Austin

Austin, Texas, 78712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.